2021 annual financial data
Spero Therapeutics 2021 Operating cash flow margin
Spero Therapeutics 2021 operating cash flow margin with verified reported value…
Direct answer
Operating cash flow margin was -2,095.99%.
Operating income was -87,971,000 USD and net income was -89,756,000 USD.
Operating cash flow was -64,346,999 USD.
Get free Spero Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3,070,000 USD
- Operating income
- -87,971,000 USD
- Net income
- -89,756,000 USD
- Operating cash flow
- -64,346,999 USD